Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - docetaxel -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - docetaxel -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - docetaxel -

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - head and neck cancer, small cell lung cancer, testicular cancer, ovarian cancer, uterine cancer, malignant lymphoma, non-small cell lung cancer, breast cancer used in conjunction with other antineoplastic drugs for the following malignant tumours: paediatric solid malignant tumours (neuroblastoma/retinoblastoma/ hepatoblastoma/central nervous system neuroblastoma, recurrent or refractory ewing?s sarcoma family tumours/nephroblastoma)

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - head and neck cancer, small cell lung cancer, testicular cancer, ovarian cancer, uterine cancer, malignant lymphoma, non-small cell lung cancer, breast cancer used in conjunction with other antineoplastic drugs for the following malignant tumours: paediatric solid malignant tumours (neuroblastoma/retinoblastoma/ hepatoblastoma/central nervous system neuroblastoma, recurrent or refractory ewing?s sarcoma family tumours/nephroblastoma)

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - head and neck cancer, small cell lung cancer, testicular cancer, ovarian cancer, uterine cancer, malignant lymphoma, non-small cell lung cancer, breast cancer used in conjunction with other antineoplastic drugs for the following malignant tumours: paediatric solid malignant tumours (neuroblastoma/retinoblastoma/ hepatoblastoma/central nervous system neuroblastoma, recurrent or refractory ewing?s sarcoma family tumours/nephroblastoma)

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - 1. relief of subjective and objective symptoms in the following diseases: acute leukaemia, malignant lymphoma, breast cancer, ovarian cancer, stomach cancer, liver cancer, urothelial cancer (bladder cancer, renal pelvic/ureteral cancer) 2. treatment of the following malignant cancer in conjunction with other anti-malignant cancer drugs: breast cancer (pre- and post-operative chemotherapy in operable cases)

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - 1. relief of subjective and objective symptoms in the following diseases: acute leukaemia, malignant lymphoma, breast cancer, ovarian cancer, stomach cancer, liver cancer, urothelial cancer (bladder cancer, renal pelvic/ureteral cancer) 2. treatment of the following malignant cancer in conjunction with other anti-malignant cancer drugs: breast cancer (pre- and post-operative chemotherapy in operable cases)

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - oxaliplatin, quantity: 5 mg/ml - injection, intravenous infusion - excipient ingredients: tartaric acid; sodium hydroxide; water for injections - oxaliplatin, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: * adjuvant treatment of stage iii colon cancer in patients who have undergone complete resection of the primary tumor. * treatment of advanced colorectal cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - oxaliplatin, quantity: 5 mg/ml - injection, intravenous infusion - excipient ingredients: tartaric acid; sodium hydroxide; water for injections - oxaliplatin, used in combination with infusional 5-fluorouracil/leucovorin is indicated for: * adjuvant treatment of stage iii colon cancer in patients who have undergone complete resection of the primary tumour * treatment of advanced colorectal cancer.